Evidence guide · UK

Peptides with testosterone (TRT): what the evidence shows for CJC-1295, ipamorelin and MK-677

Men on testosterone are adding growth hormone peptides, MK-677, BPC-157 and TB-500. A new review finds no study of these combinations for muscle, strength or function. What the trials of each one show for muscle, strength and safety.

Review type: research summary. This page summarises published research and product labels, cited below.

Men on testosterone therapy (TRT) are increasingly adding peptides: growth hormone boosters such as CJC-1295, ipamorelin, sermorelin and tesamorelin, the oral pill ibutamoren (MK-677), and the so-called recovery peptides BPC-157 and TB-500. On 19 November 2026 two authors from the Department of Urology at Northwell Health in New Hyde Park, New York, Robert Liberto and Jonathan Davila, published a review of the human evidence for these add-ons in the American Journal of Men's Health. Its title sums up the finding: "Popularity without proof".

Short answer: no published study has measured what these peptide add-ons do for body composition, strength or physical function in men taking testosterone. On their own, the growth hormone boosters raise growth hormone and, in most trials, IGF-1, and some add a kilogram or two of lean or fat-free mass, but trials have not shown matching gains in strength or function, and the review notes that part of an ibutamoren weight gain may have been fluid. The best data come from older adults and people with specific medical conditions, not young men chasing a physique. The safety record includes higher blood sugar with ibutamoren and an early-stopped trial over heart failure, and products sold online have been found to be impure or contaminated.

Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.

What goes into a "TRT plus peptides" protocol

The review groups the add-ons into two classes. Growth hormone secretagogues push the pituitary gland to release more growth hormone. Some copy the hormone GHRH (sermorelin, CJC-1295 and tesamorelin); others copy the hunger hormone ghrelin (GHRP-2, GHRP-6, ipamorelin and ibutamoren, which is a pill rather than a peptide). The second class, BPC-157 and TB-500, is promoted for healing and recovery. Testosterone use itself has grown: prescription-monitoring data from participating US states show 27% more people filling testosterone prescriptions in 2022 than in 2018, with the most notable rises among people aged 35 to 44 (58%) and 45 to 54 (35%).

Studies of peptides with testosterone

The review found no trial of any of these peptides combined with testosterone that measured muscle, fat, strength or function. The closest is a 2017 retrospective chart review of 105 men on testosterone who wanted more lean mass and less fat and were prescribed GHRP-2, GHRP-6 and sermorelin three times a day. Only 14 met the strict adherence criteria. In those 14 men, average age 33, IGF-1 rose from 159.5 to 239.0 ng/mL over an average of 134 days. There was no control group, and body composition was not measured.

What extra growth hormone does in fit young adults

Growth hormone itself shows the pattern. A 2008 systematic review of randomised trials in healthy, physically fit people (303 given growth hormone, mean age 27) found lean body mass rose by 2.1 kg compared with controls, but strength and exercise capacity did not seem to improve. Soft-tissue swelling (oedema) and fatigue were more common, and the authors concluded that claims of better physical performance are not supported.

Peptide by peptide

Sermorelin: in 11 healthy men aged 64 to 76, six weeks of nightly injections raised night-time growth hormone but did not change IGF-1, weight or scan measures of muscle and fat; two of six strength measures improved. In a 16-week single-blind study of a closely related GHRH analogue in 19 adults aged 55 to 71, lean body mass rose in the men only, sleep quality did not change, and blood fats rose for a time before settling by the end of the study. The review notes that sermorelin was once FDA-approved and was withdrawn in 2008 for manufacturing reasons, and that none of its trials enrolled young men.

CJC-1295: in two small trials in healthy adults aged 21 to 61, single injections raised growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days, with no serious adverse reactions reported. According to the review, no human study has measured its effect on body composition, strength or function, and a phase 2 trial was stopped after a participant died of a heart attack, although causality was not established.

Ipamorelin: the only human trial gave it into a vein for up to seven days after bowel surgery, in 114 adults, to speed recovery of the gut. It found no significant difference from placebo. No human trial has measured muscle, strength or function. GHRP-2 and GHRP-6 have no human trials of body composition, strength or function; the review notes that they also raise cortisol and prolactin, and that a GHRP-2 infusion increased food intake by 10 to 34%, which could explain some apparent gains.

Tesamorelin: the only one with a current FDA approval, as Egrifta WR, for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its label says it is not indicated for weight loss, that its long-term cardiovascular safety has not been established, and that it can cause fluid retention, glucose intolerance and raised IGF-1; it must not be used with active cancer or in pregnancy. A 2026 meta-analysis of five trials in people with HIV found less visceral fat (27.71 cm² less) and 1.42 kg more lean body mass, with no change in body mass index. The review notes that strength was not measured alongside the lean-mass gain.

Ibutamoren (MK-677): a two-year randomised trial in 65 healthy adults aged 60 to 81 found that 25 mg a day raised growth hormone and IGF-1 to young-adult levels and increased fat-free mass by 1.1 kg, against a 0.5 kg fall on placebo, but strength and function did not change. Body weight rose by 2.7 kg, fasting blood glucose rose by an average of 0.3 mmol/L and insulin sensitivity fell; increased appetite, mild swelling and muscle pain were the commonest side effects. In 24 obese men aged 18 to 50, eight weeks raised fat-free mass without changing total or visceral fat, and a glucose tolerance test worsened. A trial in 123 older adults recovering from hip fracture was stopped early because of a heart failure safety signal.

BPC-157 and TB-500

The review describes the evidence for BPC-157 as largely from animal and cell studies, with three small human pilot studies and no controlled efficacy data, and finds no published human trials of TB-500 in tendon or muscle; much of the literature studies the parent protein, thymosin beta-4, rather than TB-500 itself. Neither has been studied with testosterone. Our pages on BPC-157 and TB-500 cover them in more detail.

What is actually in the vials

A Belgian analysis of the ten most frequently encountered falsified peptide drugs, bought from three suspected illegal online pharmacies, found the amount of drug per unit varied widely and purity for cysteine-containing peptides ranged from 5% to 75%. One sample contained lead, and several had toxic metal concentrations up to ten times the international limit for injectable drugs, with arsenic in its more toxic inorganic form. A US study of top-ranking websites selling steroids found that 87% offered anabolic steroids, injectable testosterone and other hormone treatments, none required a prescription, and 75% gave cycling and stacking advice.

Sport

The 2026 World Anti-Doping Agency list bans growth hormone releasing factors at all times, naming CJC-1295, sermorelin and tesamorelin, ibutamoren and ipamorelin, and GHRP-2 and GHRP-6. BPC-157 is banned at all times as a non-approved substance.

Evidence grades

  • Peptides added to testosterone for muscle, strength or recovery: Insufficient. No study has measured these outcomes.
  • Growth hormone boosters raising growth hormone levels: Moderate. Several randomised trials, mostly small and in older adults or patients; IGF-1 rose in most of them.
  • Growth hormone boosters for lean or fat-free mass: Limited. Gains of about 1 to 1.5 kg where reported, in older adults and patients. The review links some of the weight gain to fluid.
  • Growth hormone boosters for strength or physical function: Limited, and the trials mostly show no improvement.
  • BPC-157 and TB-500 for recovery in people: Insufficient.
  • Ibutamoren and blood sugar: Evidence of harm. A two-year randomised trial found higher fasting glucose and lower insulin sensitivity.

Our view

Adding growth hormone peptides to testosterone rests on plausibility, not trial results. Testosterone itself is a prescription treatment for confirmed low testosterone, and the Endocrine Society advises diagnosing that only in men with symptoms and signs and consistently low morning blood levels, and not starting it in men planning to father a child soon. The peptides can raise hormone levels and the number on a body-composition scan, but in the trials that measured them that has not translated into strength or function.

  • Do not treat these products as supplements. They are prescription or unapproved drugs, and "research use only" vials have unknown contents and dose.
  • If you are on testosterone, tell your prescriber about every peptide you use, including where you got it.
  • If you use a growth hormone booster, ask about checking fasting glucose or HbA1c, and report new swelling, breathlessness, joint pain or tingling in the hands.
  • If you compete under anti-doping rules, every growth hormone booster named here and BPC-157 are banned at all times.

UK rules

Under regulation 2 of the Human Medicines Regulations 2012, a medicinal product includes any substance presented as treating or preventing disease, or given to people to restore, correct or modify a physiological function through a pharmacological, immunological or metabolic action. A peptide injected to raise growth hormone fits that definition whatever the label says. Report suspected side effects of any medicine, including products bought online, through the MHRA's Yellow Card scheme.

FAQ

Does adding CJC-1295 and ipamorelin to TRT build more muscle?

There is no trial evidence either way. No human study has measured muscle, strength or function with either peptide, alone or with testosterone. Related growth hormone boosters add some fat-free mass without improving strength.

Is MK-677 a peptide, and is it safe?

Ibutamoren (MK-677) is a pill, not a peptide, that acts on the same receptor as ipamorelin. In a two-year trial in older adults it raised fasting blood glucose and lowered insulin sensitivity, and a hip-fracture trial was stopped early over heart failure. It is not an approved medicine.

Is tesamorelin approved?

Yes, in the US, as Egrifta WR, for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its US label says it is not indicated for weight loss.

Do these peptides raise testosterone?

No. They act on growth hormone, not testosterone. In the 2017 study of men already on testosterone, the peptides raised IGF-1, a marker of growth hormone activity.

Sources

These are the documents this page relies on.

  1. Liberto R, Davila J. Popularity without proof: a narrative review of peptide adjuncts to testosterone therapy in body composition and functional-driven use. Am J Mens Health. 2026;20(6):15579883261510877American Journal of Men's Health (PubMed 43056390)
  2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744Journal of Clinical Endocrinology & Metabolism (PubMed 29562364)
  3. Selinger S, Thallapureddy A. Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018-2022. PLoS One. 2024;19(8):e0309160PLoS One (PubMed 39196907)
  4. Sigalos JT, Pastuszak AW, Allison A, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017;11(6):1752-1757American Journal of Men's Health (PubMed 28830317)
  5. Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008;148(10):747-758Annals of Internal Medicine (PubMed 18347346)
  6. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96Metabolism (PubMed 9005976)
  7. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479Journal of Clinical Endocrinology & Metabolism (PubMed 9141536)
  8. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805Journal of Clinical Endocrinology & Metabolism (PubMed 16352683)
  9. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534International Journal of Colorectal Disease (PubMed 25331030)
  10. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611Annals of Internal Medicine (PubMed 18981485)
  11. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369Journal of Clinical Endocrinology & Metabolism (PubMed 9467542)
  12. Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183-189Archives of Gerontology and Geriatrics (PubMed 21067829)
  13. Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12Obesity Research & Clinical Practice (PubMed 41545261)
  14. Egrifta WR (tesamorelin) for injection: US prescribing information (DailyMed)Theratechnologies via DailyMed, US National Library of Medicine
  15. Janvier S, Cheyns K, Canfyn M, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807Talanta (PubMed 30029448)
  16. McBride JA, Carson CC 3rd, Coward RM. The availability and acquisition of illicit anabolic androgenic steroids and testosterone preparations on the Internet. Am J Mens Health. 2018;12(5):1352-1357American Journal of Men's Health (PubMed 27170675)
  17. World Anti-Doping Code International Standard: Prohibited List 2026 (sections S0 and S2.2.4)World Anti-Doping Agency
  18. The Human Medicines Regulations 2012, regulation 2legislation.gov.uk
  19. Yellow Card: report a side effectMedicines and Healthcare products Regulatory Agency